Thrombosis and cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Dotsenko, O ^a,b   Kakkar, A K ^a,b  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ARTICLE; BLEEDING; CANCER; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPRESSION THERAPY; DEATH; DEEP VEIN THROMBOSIS; DRUG TREATMENT FAILURE; ECHOGRAPHY; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY PREVENTION; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

HUMANS; NEOPLASMS; RISK FACTORS; THROMBOSIS;

EID: 33749624851     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl242     Document Type: Article

References (41)

1. Kakkar AJ, Levine M, Pinedo HM et al. Venous thrombosis in cancer patients: Insights from the FRONTLINE survey. Oncologist 2003; 8: 381-388.
2. Goldaheber SZ, Tapson VF, DVT FREE Steering Committee, A prospective registry of 5,451 patients with unltrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 259-262.
3. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: New insights and innovations in thrombosis and cancer. J Thromb Haemost 2003; 1: 1456-1463.
4. Sorensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
5. Baron JA, Gridley G, Weiderpass E et al. Venous thromboembolism and cancer. Lancet 1998; 351 (9109): 1077-1080.
6. Heit JA, O'Fallon WM, Petterson TM et al. Relative Impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med 2002; 162-1245-1248.
7. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000; 160: 809-815.
8. Levitan N, Dowlati A, Remick SC et al. Rates of Initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using Medicare claims data. Medicine 1999; 78: 285-291.
9. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579.
10. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: Is heparin prophylaxis justified? South Med J 1980: 73: 841-843.
11. Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
12. Prandoni P, Lensing AWA, Buller HR, Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133.
13. Kakkar AK, DeRuvo N, Chinswangwatanakul V et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-1005.
14. Falanga A, Zacharski L. Deep vein thrombosis in cancer: The scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
15. Geerts WH, Pineo GF, Heit JA et al. Prevention at venous thromboembolism. Chest 2004; 126: 338S-400S.
16. Horton J. Venous thrombotic events in cancer: The bottom line. Cancer Control 2005; 12 (Suppl 1): 31-37.
17. Piccioli A, Prandoni P, Ewenstein BM et al. Cancer and venous thromboembolism. Am Heart J 1996; 132: 850-855.
18. International Multicentre Trial. Prevention of fatal pulmonary embolism by low doses of heparin. Lancet 1975; 2: 45-51.
19. Clagett GP, Reisch JS. Preventon of venous thromboembolism in general surgical patients: Results of meta-analysis. Ann Surg 1988; 208: 227-240.
20. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099-1103.
21. McLeod RS, Geerts WH, Sniderman KW et al. Subcutaneous heparin versus low-molecular-weight heparih as thromboprophylaxis in patients undergoing colorectal surgery: Results of the Canadian Colorectal DVT Prophylaxis Trial: A randomized, double-blind trial. Ann Sung 2001; 233: 438-444.
22. Mismetti P, Laporte S, Darmon JY et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism In general surgery. Br J Surg 2001; 88: 913-930.
23. Bergqvist D, Agnelli G, Cohen AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer, N Eng J Med 2002; 346: 975-980.
24. Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: A role for prolonged thromboprophylaxis. Cancer Treatment Rev 2002; 28: 141-144.
25. Agnelli G, Bergqvist D, Cohen AT, et al. PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery, Br J Surg 2005 Oct; 92(10): 1212-1220.
26. Leizorovicz A, Cohen AT, Turpie AGG et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
27. Bauersachs RM. Fondaparinux: An update on new study results. Eur J Clin Invest 2005; 35 (suppl 1): 27-32.
28. Alikhan R, Cohen AT, Combe S et al. Prevention of venous thromboembolism in medical patients with enoxaparin: A subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-346.
29. Levine M, Hirsh J, Gent M et al. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889.
30. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 suppl): 401S-28S.
31. Koopman MM, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334(11): 682-687.
32. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334(11): 677-81.
33. Merli G, Spiro TE, Olsson CG et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134(3): 191-202.
34. Harrison L, McGinnis J, Crowther M et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998; 158: 2001-2003.
35. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
36. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 2002; 162(15): 1729-1735.
37. Lee AY, Levine MN, Baker RI et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146-153.
38. Siragusa S, Cosmi B, Piovella F et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patents with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996; 100: 269-277.
39. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
40. Altinbas M, Coskun HS, Er O et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2(8): 1266-1271.
41. Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patents with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135.